MedDataX Logo

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

NCT ID: NCT03305133

Last Updated: 2020-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-26

Study Completion Date

2018-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with large-cell lung neuroendocrine carcinoma (NEC), whatever the stage of the disease, and to correlate this parameter to clinical data at the time of diagnosis, therapeutic response and survival. Large-cell NECs present a bad prognostic and there is no evidence of treatment for these patients with advanced disease in second ligne of treatment at that time. To demonstrate the PD-L1 expression in this type of cancer might have a major therapeutic impact in a close future to access immunotherapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NCT02785562

Lung Cancer
COMPLETED NA

Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study

NCT03998332

Survival Outcomes of Patients With Pulmonary LCNEC
COMPLETED

Prognostic Value of PD-L1 in NSCLC

NCT03078959

Carcinoma, Non-Small-Cell Lung
UNKNOWN

Radiomics for prEdiction of lunG cAncer biologY

NCT05819905

Non Small Cell Lung Cancer PET/CT PD-L1 +1 more
UNKNOWN

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

NCT05985330

Metastatic Non-small Cell Lung Cancer
RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Large Cell Lung Cancer Neuroendocrine Carcinoma of Lung (Diagnosis)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunohistochemistry

The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged \> or = 18 years
* Diagnosis of Large-cell NEC confirmed by centralised reading
* Tumoral materials available and readable for PD-L1 labeling

Exclusion Criteria

* Other type of Lung cancers
* Tumoral material not available or not readable for centralised reading
* Tumoral material not available or not readable for PD-L1 labeling
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Groupe Francais De Pneumo-Cancerologie

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dominque Arpin, MD

Role: PRINCIPAL_INVESTIGATOR

Service de pneumologie et oncologie thoracique - Hôpital Nord-Ouest - F-69400 Villefranche sur Saône

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier D Argenteuil

Argenteuil, VAL D'oise, France

Site Status

Site 12

Aix-en-Provence, , France

Site Status

Centre Hospitalier Universitaire

Angers, , France

Site Status

Site 05

Bastia, , France

Site Status

Site 22

Beauvais, , France

Site Status

Centre Hospitalier du Morvan

Brest, , France

Site Status

Site 43

Caen, , France

Site Status

Site 48

Clermont-Ferrand, , France

Site Status

Site 33

Créteil, , France

Site Status

Site 32

Elbeuf, , France

Site Status

Site 04

Gap, , France

Site Status

Centre Hospitalier Les Oudairies

La Roche-sur-Yon, , France

Site Status

Centre Hospitalier Universitaire DUPUYTREN

Limoges, , France

Site Status

Hospital du Cluzeau

Limoges, , France

Site Status

Site 00

Limoges, , France

Site Status

Centre Hospitalier Lyon Sud

Lyon, , France

Site Status

Site 25

Mantes-la-Jolie, , France

Site Status

Site 06

Marseille, , France

Site Status

Site 01

Meaux, , France

Site Status

Site 42

Orléans, , France

Site Status

Hospital Saint Antoine

Paris, , France

Site Status

Site 26

Paris, , France

Site Status

Site 19

Périgueux, , France

Site Status

Site 02

Reims, , France

Site Status

Site 18

Rouen, , France

Site Status

Site 17

Rouen, , France

Site Status

Site 14

Toulon, , France

Site Status

Site 11

Villefranche-sur-Saône, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GFPC 03-2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer
NCT01956331 COMPLETED
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients
NCT03748901 COMPLETED
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
NCT04589013 COMPLETED
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
NCT03092739 COMPLETED
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
NCT04886401 RECRUITING
Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
NCT02855281 COMPLETED
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
NCT06833229 RECRUITING
Endoscopic Treatment of Bronchial Carcinoid Tumors
NCT03723499 COMPLETED
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
NCT00826683 COMPLETED PHASE3
PD-L1 Expression in Lung Cancer
NCT04992715 UNKNOWN PHASE2
Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study
NCT05195385 RECRUITING NA
Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
NCT04452292 COMPLETED NA
Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer
NCT06244355 RECRUITING
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
NCT00759382 UNKNOWN
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
NCT07192991 NOT_YET_RECRUITING
A Clinico-biological Database of Lung Cancers
NCT03387865 RECRUITING
Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer
NCT04939324 UNKNOWN NA
Pronostic and Predictive Value of EMT in Localized Lung Cancer
NCT03509779 RECRUITING
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
NCT02827344 COMPLETED
OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients
NCT04548960 UNKNOWN NA
Epidemiological Study to Assess the Prevalence of Lung Cancer
NCT03976804 UNKNOWN NA
Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer
NCT01799395 TERMINATED
GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors
NCT03645915 COMPLETED
Study on Fluids Associated to Lung Cancer
NCT02853006 COMPLETED NA
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
NCT01700582 COMPLETED